



Formulary



Formulary/STEP

STEP Edit: No TAR required with ≥ 30 day trial of oxybutynin ER in the last 120 days.




Preferred Non-Formulary

Requires trial of 2 long-acting formulary agents: oxybutynin ER, trospium ER (STEP), tolterodine ER (STEP). Minimum 30 day trial for each.


Trial & failure with 2 of 3 ER agents

TAR



Trial & failure with 2 of 3 ER agents & Toviaz


TAR




Non-Formulary

Unless otherwise specified, requires trial of fesoterodine (Toviaz) and 2 long-acting formulary agents: oxybutynin ER, trospium ER (STEP), tolterodine ER (STEP).

Minimum 30 day trial for each.



Rx NDCs not covered, use OTC NDC.



Limited to members with contraindication to orally administered treatment AND ≥30 day t/f Oxytrol Patch OTC.

**Partnership Healthplan of California
Formulary Flow Diagram for Overactive Bladder Treatment**

By Jordan Sumodobila, PharmD 7/5/2016

IR: Immediate Release. **ER:** Extended Release. **QL:** Quantity Limit. **TAR:** Treatment Authorization Request
Rx: Prescription required by law **OTC:** Over-the-Counter *but* prescription required for plan reimbursement
NDC: National Drug Code (similar to UCP, a unique product identifier)